Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy

NCT00880191 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00880191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00880191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2009
Completion date
May 31, 2015
Enrollment
430 (actual)
Sites
247

Conditions

As the registry lists them; a condition with its own page is linked.

nausea and vomiting, unspecified adult solid tumor, protocol specific